What is Capricor Therapeutics's net investment in lease?

Capricor Therapeutics (CAPR) reported net investment in lease of $13.16M in Q1 2026.

How has Capricor Therapeutics's net investment in lease changed year-over-year?

Capricor Therapeutics's net investment in lease increased by 1066.8% year-over-year, from $1.13M to $13.16M.

Capricor Therapeutics CAPR Net Investment in Lease

Net Investment in Lease at other companies

Sarepta Therapeutics, Inc.SRPT

——

PTC TherapeuticsPTCT

——

Celldex TherapeuticsCLDX

——

VericelVCEL

——

Dyne Therapeutics, Inc.DYN

——

Viridian Therapeutics, Inc.VRDN

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$36.8M-47.2%

Net income-$33.9M-39.2%

EPS (diluted)-$0.59-11.3%

Balance sheet

See full

Cash & equivalents$105.4M+266%

Total debt$14.8M+1,083%

Total equity$278.7M+118%

Total assets$326.3M+112%

Cash flow

See full

Operating cash flow-$29.3M-355%

CapEx$5.1M+472%

Free cash flow-$34.4M-369%

Valuation

See full

Market cap$1.71B+303%

Enterprise value$1.62B+308%

Profitability

See full

Operating margin-778.8%-1,038pp

Net margin-736.6%-981pp

FCF margin-563.9%-954pp

Returns & leverage

See full

Return on equity-56.4%-11.3pp

Debt / equity0.1×0.0×

Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Capricor Therapeutics's net investment in lease?: Capricor Therapeutics (CAPR) reported net investment in lease of $13.16M in Q1 2026.
How has Capricor Therapeutics's net investment in lease changed year-over-year?: Capricor Therapeutics's net investment in lease increased by 1066.8% year-over-year, from $1.13M to $13.16M.